LitAlert ~~ GeneLit.com

    • Rare presentations can suggest more than one rare condition: Striking personal and family cancer history in a patient with both CDKN2A and BRCA1 pathogenic variants.
    • Trupiano N, Koeppe E, Jacobs MF, Else T, Cha KB.
    • JAAD Case Rep. 2022 Nov 7 [eCollection 2023 Jan];31:42-45. doi: 10.1016/j.jdcr.2022.10.034.
    • Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients.
    • Nurmi AK, Suvanto M, Dennis J, Aittomäki K, Blomqvist C, Nevanlinna H.
    • Cancers (Basel). 2022 Dec 14;14(24):6158. doi: 10.3390/cancers14246158.
    • Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
    • Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U.
    • Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789.
    • Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Dec 12;12:1010158. doi: 10.3389/fonc.2022.1010158.
    • Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer.
    • Ray F.
    • Precision Oncology News. 2022 Dec 12.